1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Θετικών Επιστημών
  4. Τμήμα Χημείας
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/9624
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAgouridis, A. P.en
dc.contributor.authorTsimihodimos, V.en
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorDimitriou, A. A.en
dc.contributor.authorTellis, C. C.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorTselepis, A. D.en
dc.date.accessioned2015-11-24T16:50:36Z-
dc.date.available2015-11-24T16:50:36Z-
dc.identifier.issn1465-6566-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/9624-
dc.rightsDefault Licence-
dc.subjectfenofibrateen
dc.subjecthigh sensitivity c-reactive proteinen
dc.subjectisoprostane 8-iso-prostaglandin f2alphaen
dc.subjectlipoprotein-associated phospholipase a2en
dc.subjectomega 3 fatty acidsen
dc.subjectrosuvastatinen
dc.subjectc-reactive proteinen
dc.subjectcoronary-heart-diseaseen
dc.subjectlipoprotein-associated phospholipase-a2en
dc.subjectactivating-factor-acetylhydrolaseen
dc.subjectlow-density-lipoproteinen
dc.subjectmiddle-aged menen
dc.subjectn-3 fatty-acidsen
dc.subjectcardiovascular-diseaseen
dc.subjectmetabolic syndromeen
dc.subjectfollow-upen
dc.titleThe effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemiaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primaryDoi 10.1517/14656566.2011.591383-
heal.identifier.secondary<Go to ISI>://000296981400002-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.1517/14656566.2011.591383-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.publicationDate2011-
heal.abstractObjective: Mixed dyslipidemia, oxidative stress and inflammation are related to a high risk for cardiovascular events. The aim of this open-label randomized study was to compare the effects of high-dose rosuvastatin, low-dose rosuvastatin plus fenofibrate and low-dose rosuvastatin plus omega 3 fatty acids on inflammation and oxidative stress indices in patients with mixed dyslipidemia. Methods: Ninety patients with mixed dyslipidemia participated in the study. Patients were randomly allocated to receive rosuvastatin 40 mg (n = 30, group R), rosuvastatin 10 mg plus fenofibrate 200 mg (n = 30, group RF) or rosuvastatin 10 mg plus omega 3 fatty acids 2 g daily (n = 30, group R Omega). Plasma and high-density lipoprotein (HDL)-associated lipoprotein-associated phospholipase A2 (LpPLA2) activities, high-sensitivity C reactive protein (hsCRP), plasma isoprostane and paraoxonase (PON1) activities were measured at baseline and after 3 months of treatment. Results: Serum concentrations of non-HDL cholesterol and low-density lipoprotein cholesterol (LDL-C) were significantly reduced in all study groups. However, these changes were more pronounced in the rosuvastatin monotherapy group. In all treatment groups a significant reduction in total plasma LpPLA2 activity was observed (by 41, 38 and 30% for groups R, RF and RW, respectively). This decrease was greater in the R and RF groups compared with the RW combination (p < 0.05). HDL-LpPLA2 activity was increased more in the RF group (+43%) compared with the R and RW groups (+ 18% and + 35%, respectively; p < 0.05 for both comparisons). In all treatment groups there was a nonsignificant reduction in plasma 8-iso-PGF2 alpha levels. A 53% reduction of hsCRP levels was observed in the R group, while in the RF and RW groups the reduction was 28 and 23%, respectively (p < 0.05 and p < 0.01 for the comparisons of group R with groups RF and RW, respectively). No significant changes were observed in PON activities in all treatment groups. Conclusion: The greater non-HDL-C- and LDL-C-lowering efficiency of rosuvastatin monotherapy along with its more potent effect on LpPLA2 activity and hsCRP levels indicate that this regimen is a better treatment option for patients with mixed dyslipidemia.en
heal.journalNameExpert Opinion on Pharmacotherapyen
heal.journalTypepeer reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ

Show simple item record
Files in This Item:
There are no files associated with this item.
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons